anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Insurance coverage for oral valganciclovir (VGCV) began in Japan in April 2023 on the basis of results, including our clinical trials for symptomatic congenital cytomegalovirus (CMV) disease. The VGCV treatment is available throughout Japan, so clinicians must consider the likelihood of hearing improvement and the possibility of neutropenia before dosing.
MATERIALS AND METHODS: We performed a substudy of an investigator-initiated, single-arm, prospective, multicenter, clinical trial in which 24 infants with symptomatic congenital CMV disease were orally administered 16 mg/kg VGCV twice daily for 6 months as an intervention. We examined the infants' baseline characteristics associated with improved hearing impairment or a severely reduced neutrophil count.
RESULTS: Of the 24 patients, 4 had normal hearing on assessment of their ear with the best hearing. Hearing impairment improved in 14 patients and did not respond to VGCV treatment in 6 patients at the 6-month hearing assessment. CMV DNA levels in plasma at baseline were higher in patients in whom hearing did not respond to treatment. A neutrophil count <500/mm3 occurred in 5 (21%) patients for the first 6 weeks and in 8 (33%) patients for the first 6 months. A neutrophil count at screening and the lowest neutrophil count over the 6 months showed the highest correlation (r = 0.477, p = 0.019).
CONCLUSIONS: Infants with a low plasma viral load at screening tend to have an improvement in hearing impairment. Clinicians should be aware of neutropenia during VGCV treatment particularly in patients with a low neutrophil count during screening.
Placebo is an opaque empty gel capsule obtained from the UZ Gasthuisberg pharmacy. These capsules are composed of 100% gelatine that will rapidly dissolve (disintegration time is 15 minutes) in the stomach without affecting the gastric motor function.
<P>PROBLEM TO BE SOLVED: To provide a skin cleanser composition which is good in foaming and foam quality (creamy property), does not leave sliminess after rinsed, is moist after dried with towel, and is excellent in stability (inhibition of odor generation and discoloration with the elapse of time).  <P>SOLUTION: This skin cleanser composition is characterized by comprising a fatty acid alkali metal salt, a fatty acid basic amino acid salt and an antioxidant. It is preferable to further comprise a metal sequestrant. The basic amino acid is desirably arginine. The antioxidant is preferably selected from hydroxyethane diphosphonic acid and its salts, and sulfite and its salts. The metal sequestrant is preferably selected from ethylene diamine tetraacetic acid and its salts.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention discloses a novel pharmaceutical composition, coenzyme Q10 emulsion and freeze-dried emulsion, and a preparation method thereof. The emulsion comprises coenzyme Q10 as the medicinal component in 0.25 %, and medicinal supplementary material including oil phase 1-20 %, emulsifier 0.01-10 %, auxiliary emulsifier 0.001-5 %, stabilizer 0-2 % and isoosmotic regulator 1-10 % as the balance. The freeze-dried emulsion contains coenzyme Q10 in 0.25-1.0 %, a freeze-dryed protective agent and water for injection as the balance. According to the ingredients of the coenzyme Q10 emulsion, the freeze-dried emulsion and the preparation method thereof, the particle diameters of both the coenzyme q10 emulsion and the freeze-dried emulsion are less than 500 nm belonging to the category of sub-nanometer emulsions. The particle diameter of the freeze-dried emulsion is not changed significantly. Before use, the freeze-dried emulsion is reconstructed by adding water, wherein the freeze-dried emulsion is quickly re-dissolved to be renewed as a sub-nanometer emulsion. Meanwhile, no crystalline is precipitated during the dilution of the freeze-dried emulsion. The initial stability test shows that the pharmaceutical composition is better in stability and light stability, compared with common solution type preparations. The safety test shows that the pharmaceutical composition meets the safety requirement and can be used for clinical intravenous injection and oral administration.
Methods for treating neoplasia, by administering  reovirus  to a Ras-mediated neoplasm, are disclosed. The  reovirus  is administered so that it ultimately directly contacts cells of the neoplasm. Human  reovirus , non-human mammalian  reovirus , and/or avian  reovirus  can be used. If the  reovirus  is human  reovirus , type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of  reovirus  can be used. Combinations of more than one type and/or strain of  reovirus  can be used, as can  reovirus  from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
Obstructive Sleep Apnea (OSA) is a common respiratory disease characterized by the occurrence of recurrent episodes of partial or total obstruction of the upper airway called hypopneas and apneas respectively. These episodes are associated with the repetitive occurrence of the desaturation-reoxygenation sequences, the so-called chronic intermittent hypoxia (IH) which is the major stimulus underlying main cardiovascular, metabolic consequences and pro-inflammatory state found in patients with OSA. Recent data from cohort studies have established that OSA is an even greater risk factor for cancer-related mortality. Hepatocellular carcinoma (HCC) is the second cancer related death worldwide and has an increasing impact in developed countries. The epidemic of metabolic syndrome (MS) plays a growing role in the occurrence of metabolic steatohepatitis (NASH) related HCC. Concerning transition from NASH to NASH-related HCC, neither the frequency nor the underlying mechanism are known. Very recently, a link between OSA (IH) and NASH has been highlighted. OSA and intermittent hypoxia should be a major worsening factor in a neoplastic context. Our hypothesis is that OSA promotes the prevalence of HCC in a context of NASH.

The objective is to compare the prevalence of OSA between patients with NASH-related and hepatitis C virus (HCV)-related HCC. In this type 3, cross-sectional, multicenter, national, non-randomized study patients suffering from a NASH-related or HCV-related hepatocellular carcinoma will be recruited. Investigators expect to show a higher prevalence of OSA in patients with HCC NASH-related but also a shorter overall survival. Complementary ex vivo studies on tumor samples will be conducted in order to explore the mechanisms by which OSA and IH would promote carcinogenesis
Traditional mat exercises were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The mat exercises were applied as a home program. The exercises were visually given with detailed explanations on a piece of paper, and they were checked by telephone every week.
Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
This is a double-blind placebo- controlled randomized pilot study with 20 patients with active AS from 2 Finnish outpatient clinics. An ileocolonoscopy will be performed to all patients. 10 patients will receive FMT with feces of one of two healthy donors, and 10 patients with their own feces during ileocolonoscopy. Ileal and colonic biopsies will be taken to assess gut wall inflammation and mucosal microbiota composition. Ileocolonoscopy will be controlled in 6 months in patients with macroscopic inflammatory lesions in the first colonoscopy. From mucosal biopsies we will assess intestinal mucosal structure, inflammasome activity, cytokine expression, and the mucin layer thickness and the amount of bacterial LPS (lipopolysaccharide), which are associated with mucosal integrity. Blood levels of zonulin and LPS as indicators of mucosal permeability and bacterial penetrance will be assessed. Fecal samples will be collected repeatedly to measure fecal calprotectin, and to assess the bacterial profile changes. From mucosal biopsies and fecal samples microbial DNA will be segregated and bacterial species sorted by rRNA- based sequence technique. Clinical activity of AS will be assessed in follow-up visits as well as repeated BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), BASFI (Bath Ankylosing Spondylitis Functional Index) and MASES (Maastricht Ankylosing Spondylitis Enthesitis Score) evaluations, and measurement of CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate). Follow-up time is 12 months.
PURPOSE:To provide a pharmaceutical preparation containing omeprazole for oral administration and effective in influencing the secretion of gastric acid in use and protecting the gastric and intestinal cells. CONSTITUTION:The objective pharmaceutical preparation for oral administration can be produced by using a core containing omeprazole as an active component in combination with an alkali-reactive compound or containing an alkali salt of omeprazole and optionally an alkali-reactive compound and coating the core with one or more inert intermediate coating layers. The intermediate coating layer is composed of (A) a tablet excipient soluble or quickly decomposable in water or a water-soluble film-forming polymeric compound (e.g. polyethylene glycol) and optionally (B) a pH-buffering alkaline compound (e.g. magnesium oxide) and is positioned between the alkali-reactive core and an enteric outer layer. The omeprazole is administered at a dose of 1-400mg/day in 1 - several separated doses.
In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
Chronic allograft nephropathy is one of dreaded complication of kidney transplant. It is one of the major determinants of long term graft survival. There are a number of factors that can contribute to chronic allograft nephropathy including chronic use of calcineurin inhibitors. Renal biopsy is the investigation of choice to detect chronic renal allograft nephropathy. renal biopsy has a number of complications . This includes infection and bleeding. The non invasive renal sono-elastography (strain and Shear Wave Imaging) technique has shown very good yield of detecting and scoring fibrosis.

In this study our aim is to determine the sensitivity and specificity of ( strain sono-elastography) in the detection and classifying of chronic allograft nephropathy as compared to transcutaneous renal biopsy
PURPOSE: An agent for promoting hair growth is provided to have an excellent hair growth promotion effect and to be able to prevent hair loss by containing saponin of Torreya plant seeds. CONSTITUTION: A hair growth promotion agent includes saponin of Torreya plant seeds as an active ingredient. The Torreya plant includes at least one selected from the group consisting of Torreya california, Torreya fargesii, Torreya grandis, Torreya jackii, Torreya nucifera and Torreya taxifolia. The saponin of Torreya plant seeds is included at 0.001 to 20 weight% based on the total weight of the promoting agent. A pharmaceutical composition for promoting hair growth contains the hair growth promoting agent. A cosmetic composition includes the hair growth promoting agent. [Reference numerals] (AA) Score; (BB) Week; (CC) Voice comparison group; (DD) Minoxidil 2%; (EE) Example 1; (FF,GG) Comparative example
PURPOSE:The titled composition promoting absorption of ubidecarenone in oral administration, obtained by blending an ubidecarenone composition with a glycerin monofatty acid ester or a propylene glycol monofatty acid ester and a liquid oil. CONSTITUTION:A ubidecarenone-containing composition is blended with (A) a glycerin monofatty acid ester or a propylene glycol monofatty acid ester (both preferably oleic ester), and (B) a liquid oil, preferably a vegetable oil (e.g., cotton seed oil, or sesame oil) or a synthetic oil (e.g., propylene glycol difatty acid ester). A blending ratio of both the components is 1pt.wt. ubidecarenone, 0.1-25pts.wt., preferably 0.2-2.5pts.wt. component A and 1-30pts.wt. component B.
OBJECTIVE: The occurrence of chylous effusion in children undergoing cardiac surgery is progressively increasing due to technical advances that have led to a rise in the number of surgeries. In this context, the objective was to describe the clinical profile of a cohort of patients at the time of chylous effusion diagnosis.
METHODS: A retrospective cohort analysis was conducted between January 2011 and July 2023, involving 23 patients, aged 0 to 18 years, treated at a quaternary university hospital in southeastern Brazil. Data were obtained from the follow-up records of the Multidisciplinary Nutritional Therapy Team (MNTT) for patients who received nutritional support after developing chylous effusion in the postoperative period of cardiac surgery.
RESULTS: The younger population predominated (median age of 6 months), with a high prevalence of malnutrition (60.9%). At the time of chylous effusion diagnosis, 83% had lymphopenia, and 74% had hypoalbuminemia. The longer the time elapsed after surgery for the onset of chylous effusion, the lower the HDL cholesterol, the lower the albumin levels, the greater the surgical complexity, the younger the patient, and the lower their weight. Hypocalcemia occurred in nearly half of the sample and hypophosphatemia in 26% of the analyzed cases.
CONCLUSIONS: There was a notable presence of lymphopenia, hypoalbuminemia, and low HDL cholesterol, as well as a high incidence of mineral imbalances, particularly hypocalcemia and hypophosphatemia, which, if untreated, may lead to unfavorable outcomes. Therefore, clinical and laboratory monitoring of children in the postoperative period of cardiac surgery is important and can aid in the early diagnosis of chylous effusion and, consequently, in the timely initiation of treatment.
FIELD: fire prevention into highly-inflammable materials. SUBSTANCE: mixture for fire-safe and explosion-proof transportation includes nitroglycerine in amount of (4+X) % by weight and water-free lactose in amount of (96-X)% by weight calculated by total mixture weight. X is from 0 to 9. In particular embodiment the mixture comprises nitroglycerine in amount of 13 % by weight and water-free lactose in amount of 87% by weight. EFFECT: possibility of international mixture transportation not only by road, rail or sea but also by air due to conversion thereof into non-explosive substance. 3 cl, 4 ex
The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen- stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.
Adenomyosis is a benign condition characterized by the presence endometrial glands and stroma within the myometrium. Its prevalence varies from 5-70%. The definitive diagnosis of adenomyosis is based mainly on histological assessment of hysterectomy specimens. This led to a concept that adenomyosis affects only parous women between 35-50 years who complain of dysmenorrhea and heavy menstrual bleeding. Magnetic Resonance Imaging (MRI) can detect adenomyosis with a sensitivity of 80%. Transvaginal ultrasound using the revised Morphological Uterus Sonographic Assessment (MUSA) criteria can detect adenomyosis non-invasively at a lower cost. Such advancements in imaging techniques allow studying the prevalence of the disease in wider range of population including young women.
INTRODUCTION: Obesity is the modern world's current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and preventive advantages for obesity management.
AREAS COVERED: Historically, rimonabant, and lorcaserin, were approved and used for managing non-syndromic obesity. Currently, orlistat, naltrexone/bupropion, glucagon-like peptide-1 receptor agonist (GLP-1 RA), and a few promising therapeutic agents are under investigation, including retatrutide, cagrilintide and orforglipron, which show promising weight reduction effects. We have developed a search string of the Medical Subject Headings (MeSH), including the terms GLP-1 RAs, obesity, and weight loss. This string was then used to perform a systematic literature search in the database including PubMed, EMBASE, MEDLINE, and Scopus up to January 31st, 2024.
EXPERT OPINION: Managing obesity often requires medical interventions, particularly in cases of severe obesity or obesity-related comorbidities. Thus, it is important to approach obesity management holistically, considering individual needs and circumstances. In our opinion, consulting with healthcare professionals is crucial to developing a personalized plan that addresses both weight loss and overall health improvement.
ASPirin in Reducing Events in the Elderly (ASPREE), a placebo-controlled prevention trial of low dose aspirin, provided the opportunity to establish a biospecimen biobank from initially healthy persons aged 70+ years for future research. The ASPREE Healthy Ageing Biobank (ASPREE Biobank) collected, processed and stored blood and urine samples at -80degC or under nitrogen vapour at two timepoints, three years apart, from a willing subset of Australian ASPREE participants. Written informed consent included separate opt-in questions for biomarker and genetic testing. Fractionated blood and urine were aliquoted into multiple low-volume, barcoded cryotubes for frozen storage within 4 hours of collection. Specially designed and outfitted mobile laboratories provided opportunities for participation by people in regional and rural areas. Detailed, high quality demographic, physiological and clinical data were collected annually through the ASPREE trial. 12,219 participants contributed blood/urine at the first timepoint, 10,617 of these older adults provided 3-year follow-up samples, and an additional 1,712 provided saliva for DNA. The mean participant age was 74 years, 54% were female and 46% lived outside major cities. Despite geographical and logistical challenges, nearly 100% of blood/urine specimens were processed and frozen within 4 hours of collection into >1.4 million aliquots. After a median of 4.7 years, major clinical events among ASPREE Biobank participants included 332 with dementia, 613 with cardiovascular disease events, 1259 with cancer, 357 with major bleeds and 615 had died. The ASPREE Biobank houses and curates a large number of biospecimens collected prior to the clinical manifestations of major disease, and 3-year follow-up samples, all linked to high quality, extensive phenotypic information. This provides the opportunity to identify or validate diagnostic, prognostic and predictive biomarkers, and potentially study biological effectors, of ageing-related diseases or maintenance of older-age good health.
To efficiently manage various apparatuses to be used in a facility.SOLUTION: An information processing system includes a connection device and information processing device. The connection device is connectable to an apparatus to be used in association with a bed. The information processing device is communicable with the connection device. The connection device receives first identification information from a device which is arranged in a facility so as to originate the first identification information, and transmits the first identification information and second identification information corresponding to the connection device to the information processing device. The information processing device includes a storage section and a processor. The storage section stores first data where the first identification information is associated with information related to the device and second data where the second identification information is associated with third identification information corresponding to the apparatus. The processor detects information related to the apparatus based on the first identification information and the second identification information received from the connection device, and the first data and the second data stored in the storage section.SELECTED DRAWING: Figure 1
Background. The growing interest in microbiota-epigenetics-immune system research stems from the understanding that microbiota, a group of micro-organisms colonized in the human body, can influence the gene expression through epigenetic mechanisms and interaction with the immune system. Epigenetics refers to changes in gene activity that are not caused by the alteration in the DNA sequence itself.Discussion. The clinical significance of this research lies in the potential to develop new therapies for diseases linked to the imbalance of these microbial species (dysbiosis), such as cancer and neurodegenerative diseases. The intricate interaction between microbiota and epigenetics involves the production of metabolites and signalling molecules that can impact our health by influencing immune responses, metabolism and inflammation. Understanding these interactions could lead to novel therapeutic strategies targeting microbiota-epigenetic pathways to improve health outcomes.Conclusion. In this context, we aim to review and emphasize the current knowledge and key concepts that link the microbiota to epigenetics and immune system function, exploring their relevance to the development and maintenance of homeostasis and susceptibility to different diseases later in life. We aim to elucidate key concepts concerning the interactions and potential effects among the human gut microbiota, epigenetics, the immune system and ageing diseases linked to dysbiosis.